US › Healthcare

ImmuCell Corporation (ICCC)

US · Healthcare · Biotechnology

$9.98+3.85%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$7.2M

Revenue YoY

+11.5%

Net profit

$1.8M

Profit YoY

+265.6%

EPS

$0.20

Net margin

25.5%

Key statistics

Market cap

$87.3M

P/E

137.3

Forward P/E

0.0

P/B

2.77

Book value

$3.46

EPS (TTM)

$0.07

52-week high

$12.10

52-week low

$4.52

50-day MA

$10.52

200-day MA

$8.19

Beta

0.55

Analyst view

Analysts rate ImmuCell Corporation a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $14.00.

Shareholding

Insiders

32.00%

Institutions

20.29%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	2.87%
Morgan Stanley - Brokerage Accounts	2.44%
Renaissance Technologies Corp	1.67%
Cresset Asset Management, LLC	1.49%
Bleichroeder LP	1.12%
Geode Capital Management, LLC	0.72%
Dimensional Fund Advisors, Inc.	0.64%
Steadtrust LLC	0.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ImmuCell Corporation — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.